STOCK TITAN

Compass Therapeutics (CMPX): Vivo funds disclose 4.0% and 0.3% ownership positions

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Compass Therapeutics, Inc. is reported as the issuer of common stock held by several Vivo Opportunity investment entities. Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC each report beneficial ownership of 7,207,573 shares of common stock, representing 4.0% of the class. Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC each report beneficial ownership of 549,487 shares, or 0.3% of the class. These ownership percentages are based on 180,087,915 shares of common stock outstanding as of July 28, 2026. Each reporting person has sole voting and sole dispositive power over its respective shares and reports ownership of 5% or less of the class.

Positive

  • None.

Negative

  • None.
Shares beneficially owned (Vivo Opportunity Fund Holdings, L.P.) 7,207,573 shares Compass Therapeutics common stock; beneficial ownership reported by Vivo Opportunity Fund Holdings, L.P.
Percent of class (Vivo Opportunity Fund entities) 4.0% Ownership percentage of Compass Therapeutics common stock reported by Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC
Shares beneficially owned (Vivo Opportunity Cayman Fund, L.P.) 549,487 shares Compass Therapeutics common stock; beneficial ownership reported by Vivo Opportunity Cayman Fund, L.P.
Percent of class (Vivo Opportunity Cayman entities) 0.3% Ownership percentage of Compass Therapeutics common stock reported by Vivo Opportunity Cayman Fund, L.P. and Vivo Opportunity Cayman, LLC
Shares outstanding 180,087,915 shares Compass Therapeutics common stock outstanding as of July 28, 2026, used to calculate ownership percentages
beneficially owns financial
"Vivo Opportunity, LLC beneficially owns 7,207,573 shares of Common Stock."
Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.
sole voting power financial
"5 | Sole Voting Power 7,207,573.00 6 | Shared Voting Power 0.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power financial
"7 | Sole Dispositive Power 7,207,573.00 8 | Shared Dispositive Power 0.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
percent of class financial
"The percentage of class is based on 180,087,915 shares of Common Stock outstanding"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
limited partnership financial
"Vivo Opportunity Fund Holdings, L.P. is a Delaware limited partnership."
A limited partnership is a legal business structure with two types of partners: at least one general partner who runs the business and bears full legal responsibility, and one or more limited partners who contribute money, share profits, and have liability capped at their investment. For investors, it matters because it separates control from financial exposure — like putting money into a store without managing it — and affects how returns, risks, taxes and transferability of ownership are handled.

FAQ

What percentage of Compass Therapeutics (CMPX) does Vivo Opportunity Fund Holdings, L.P. own?

Vivo Opportunity Fund Holdings, L.P. beneficially owns 7,207,573 shares of Compass Therapeutics common stock, representing 4.0% of the outstanding class, based on 180,087,915 shares outstanding as of July 28, 2026.

How many Compass Therapeutics (CMPX) shares does Vivo Opportunity Cayman Fund, L.P. hold?

Vivo Opportunity Cayman Fund, L.P. beneficially owns 549,487 shares of Compass Therapeutics common stock, which represents 0.3% of the class, calculated using 180,087,915 shares outstanding as of July 28, 2026.

What is the total Compass Therapeutics (CMPX) share count used to calculate Vivo’s ownership?

The ownership percentages for the Vivo entities are calculated using 180,087,915 shares of Compass Therapeutics common stock outstanding as of July 28, 2026, as reported in the company’s Form 10-Q filed on August 6, 2026.

Do the Vivo Opportunity entities share voting power over Compass Therapeutics (CMPX) shares?

Each Vivo entity reports sole voting power and sole dispositive power over its respective Compass Therapeutics shares, and no shared voting or dispositive power is reported for any of the positions.

Why do Vivo Opportunity entities report ownership of 5 percent or less of Compass Therapeutics (CMPX)?

Each reporting Vivo entity discloses ownership of 4.0% or 0.3% of Compass Therapeutics common stock, so each individually holds 5 percent or less of the class, as reflected in the ownership-of-5-percent-or-less disclosure.

Who controls the Compass Therapeutics (CMPX) shares held by the Vivo limited partnerships?

The shares of Compass Therapeutics held by Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. are controlled by their respective general partners, Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC, which each report matching beneficial ownership and powers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





20454B104

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The number represents shares of common stock, par value $0.0001 per share (the "Common Stock") of Compass Therapeutics, Inc. (the "Issuer") held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percentage of class is based on 180,087,915 shares of Common Stock outstanding, as of July 28, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percentage of class is based on 180,087,915 shares of Common Stock outstanding, as of July 28, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The percentage of class is based on 180,087,915 shares of Common Stock outstanding, as of July 28, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The percentage of class is based on 180,087,915 shares of Common Stock outstanding, as of July 28, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.


SCHEDULE 13G



Vivo Opportunity Fund Holdings, L.P.
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner
Date:08/14/2026
Vivo Opportunity, LLC
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:08/14/2026
Vivo Opportunity Cayman Fund, L.P.
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity Cayman, LLC, General Partner
Date:08/14/2026
Vivo Opportunity Cayman, LLC
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:08/14/2026